Analysts think CNTB stock price could increase by 838%
Feb 23, 2025, 12:25 PM
-8.06%
What does CNTB do
Connect Biopharma Holdings, based in San Diego, develops therapies for T cell-driven inflammatory diseases and went public on March 19, 2021. Its lead candidates include rademikibart for atopic dermatitis and asthma, and icanbelimod for ulcerative colitis.
3 analysts think CNTB stock price will increase by 837.82%. The current median analyst target is $8.16 compared to a current stock price of $0.87. The lowest analysts target is $8.08 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.